Some patients saw1,4,5:
Some patients saw1,4,5:
CIBINQO is an oral, once-daily treatment option1:
Well-Studied Safety Profile in AD population of ~3800 patients
representing more than 5000 patient-years of exposure6
CIBINQO has a BOXED WARNING for serious infections, mortality, malignancy, MACE, and thrombosis1
Explore commercial coverage for CIBINQO
Help eligible, commercially insured patients gain access to copay savings*